Understanding why some IDH-mutant cancers resist treatment with PARP inhibitors
Official title: Elucidating mechanisms of PARP inhibitor resistance in IDH-mutant cancers
Funded at Yale University · NIH-11070236 · Data updated 2026-11-12
This study is looking into why some patients with IDH-mutant cancers, like acute myeloid leukemia, stop responding to a type of treatment called PARP inhibitors that are meant to help by targeting problems with DNA repair, so we can find better ways to help those patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $34,522 |
| NIH project number | 1F30CA291077-01A1 |
| Project ID | NIH-11070236 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with IDH-mutant cancers, particularly those who have experienced resistance to PARP inhibitor treatments.
✕Less likely to help
Patients without IDH mutations or those with cancers not related to the study focus may not benefit from this research.
What this research studies
This research investigates the mechanisms behind resistance to PARP inhibitors in cancers with IDH mutations, such as acute myeloid leukemia. The study focuses on how these mutations affect DNA repair processes, making some tumors initially sensitive to treatments but later resistant. By analyzing the genetic and molecular changes that occur in these cancers, the research aims to identify why certain patients do not respond to PARP inhibitors, which are designed to exploit DNA repair defects. The findings could lead to improved treatment strategies for patients with IDH-mutant cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with IDH-mutant cancers who currently do not respond to PARP inhibitors.
How similar studies have gone: Previous studies have successfully identified mechanisms of PARP inhibitor resistance in other cancer types, suggesting that this approach may yield valuable insights for IDH-mutant cancers as well.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Colon-Rios, Daniel Andrés — Yale University
- Study coordinator: Colon-Rios, Daniel Andrés
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.